Biotie Therapies Oyj  

(Public, HEL:BTH1V)   Watch this stock  
Find more results for BTH1V
0.229
-0.001 (-0.43%)
Jul 28 - Close
HEL real-time data - Disclaimer
Currency in EUR
Range 0.23 - 0.23
52 week 0.21 - 0.36
Open 0.23
Vol / Avg. 781,612.00/513,677.00
Mkt cap 102.26M
P/E     -
Div/yield     -
EPS -0.01
Shares 446.55M
Beta     -
Inst. own     -
Jul 30, 2014
Q2 2014 Biotie Therapies Oyj Earnings Call - 3:00PM GMT+3 - Add to calendar
Jul 30, 2014
Q2 2014 Biotie Therapies Oyj Earnings Release Add to calendar
May 21, 2014
Biotie Therapies Oyj at BioCentury Publications BioEquity Europe Conference
May 9, 2014
Q1 2014 Biotie Therapies Oyj Earnings Conference Call - Webcast
May 9, 2014
Q1 2014 Biotie Therapies Oyj Earnings Release
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -31.04% 22.64%
Operating margin -27.18% 6.96%
EBITD margin - 7.62%
Return on average assets -5.38% 5.34%
Return on average equity -7.91% 8.05%
Employees 37 -
CDP Score - -

Address

Tykistokatu 6
TURKU, 20520
Finland
+358-2-2748900 (Phone)
+358-2-2748910 (Fax)

Website links

Description

Biotie Therapies Oyj (Biotie Therapies Corporation) is a Finland-based biopharmaceutical company. It is a drug discovery and development company focused on the development of drugs for neurodegenerative and psychiatric disorders, such as Parkinson�s disease, Alzheimer�s disease and other cognitive disorders, alcohol and drug addictions and post traumatic stress disorder, as well as inflammatory and fibrotic liver disease.. It has a broad range of small molecule and biological drug candidates at different stages of clinical and pre-clinical development. The Company has alliances with global pharmaceutical companies such as Lundbeck and Roche. As of December 31, 2011, the Company operated four wholly owned subsidiaries, including Biotie Therapies International Oy, Biotie Therapies GmbH, based in Germany, Biotie Therapies Holding AG, based in Switzerland and Biotie Theriapies Inc, based in the United States.

Officers and directors

William M. Burns Chairman of the Board
Age: 66
Timo Veromaa M.D., Ph.D. President, Chief Executive Officer, Member of the Management Team
Age: 54
David Cook Chief Financial Officer, Member of the Management Team
Age: 47
Mehdi Paborji PhD Chief Operating Officer, Member of the Management Team
Age: 59
Stephen Bandak M.D. Chief Medical Officer, Member of the Management Team
Age: 64
Merja Karhapaa Director
Age: 52
Bernd Kastler Director
Age: 65
Ismail Kola Ph.D. Director
Age: 57
Guido Magni M.D., Ph.D. Director
Age: 61